Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
20.72
+0.67 (3.34%)
At close: Oct 13, 2025, 4:00 PM EDT
20.51
-0.21 (-1.01%)
After-hours: Oct 13, 2025, 6:08 PM EDT
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 342 employees as of December 31, 2024. The number of employees increased by 46 or 15.54% compared to the previous year.
Employees
342
Change (1Y)
46
Growth (1Y)
15.54%
Revenue / Employee
$770,365
Profits / Employee
-$272,722
Market Cap
2.48B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 342 | 46 | 15.54% |
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Dec 31, 2020 | 54 | 25 | 86.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ARQT News
- 7 days ago - FDA Approves Arcutis' ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 - GlobeNewsWire
- 10 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - Arcutis Biotherapeutics to Host Virtual Investor Day and Report Third Quarter 2025 Financial Results on October 28, 2025 - GlobeNewsWire
- 26 days ago - Arcutis To Present Multiple New ZORYVE® (roflumilast) Data Analyses at European Academy of Dermatology and Venereology Congress - GlobeNewsWire
- 27 days ago - Allure Magazine Honors Arcutis' ZORYVE® (roflumilast) with Prestigious Best of Beauty Breakthrough Award - GlobeNewsWire
- 4 weeks ago - Arcutis Biotherapeutics, Inc. (ARQT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 5 weeks ago - Arcutis Biotherapeutics, Inc. (ARQT) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 5 weeks ago - Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% to Expand Indication for Treatment of Plaque Psoriasis in Children Ages 2 to 5 - GlobeNewsWire